Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
6d
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback